Detail akcie MetaVia Rg online

Business Summary: MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, MetaVia Inc revenues was not reported. Net loss decreased 51% to $11M. Lower net loss reflects Research and development - Balancing val decrease of 67% to $5.7M (expense), General and administrative decrease of 27% to $4M (expense), Fair Value Adjustments on Other Asse increase from $94K to $194K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$40.97 to -$8.33.